Urintel

Urine Drug Testing (UDT), also known as Urine Drug Screens (UDS), are commonly used in the clinical setting by primary care and pain management clinicians. UDT, especially by immunoassay, has been used to monitor abstinence from illicit drugs and to confirm adherence to maintenance drugs, in emergency departments to support both acute treatment decisions and efforts to prevent future events (illicit drug use is considered a marker for future trauma), in pain clinics, and in primary care settings”.

AN EQUAL PLAYING FIELD: A standard practice to interpret these urine screens by immunoassay has been lacking for years, and as such patients and providers have suffered innumerably.

The time has come for individualized patient care, guidance for clinicians (and support for their clinical decisions), and a double check for patients!

This robust tool allows the user to better understand appropriate decision parameters and whether or not the assessment of lab results considers false negatives or positives and drug interactions when evaluating their urine screen results, the purpose of which is to improve communications and encourage patient safety and positive outcomes.

It will help clinicians decipher all the potential permutations and more uniformly arrive at a therapeutic decision. It will help managed care third party payers to uniformly assess logical reasoning for approval and payment for immunoassay and definitive testing by chromatography. This application considers all of these parameters and continued development will incorporate even more individualized patient uniqueness.

Privacy Policy and Terms of Use: https://www.remitigate.com/terms-and-privacy-policy/